A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Part of paid clinical trials in Chula Vista, California.

Sponsor
Marea Therapeutics
Study ID
NCT07199309
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hypertriglyceridemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • MAR001 — DRUG
    Subcutaneous Injection
  • Placebo — DRUG
    Subcutaneous Injection

Study Details

The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.

Key Dates

Start date
Sep 26, 2025
Status verified
Nov 2025
Primary completion
Jul 31, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MAR001 Dose
    Subcutaneous Injection
  • Placebo Comparator: Matching Placebo

Primary Outcome Measure

Change from baseline in TG area under the curve after a mixed meal [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Marea Site 301Chula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By research site
Marea· Chula Vista, CA

Related Studies